EQS-Adhoc: Viromed Medical AG expects dynamic growth and announces forecast for 2025 and 2026
Werte in diesem Artikel
|
EQS-Ad-hoc: Viromed Medical AG / Key word(s): Forecast Werbung Werbung Viromed Medical AG expects dynamic growth and announces forecast for 2025 and 2026 Pinneberg, June 30, 2025 – Viromed Medical AG ("Viromed"; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology, expects dynamic sales growth in the coming financial years. In detail, revenue is expected to rise from EUR 1.37 million in 2024 to around EUR 8 million to EUR 10 million in 2025 and to increase almost tenfold to around EUR 80 million in 2026. The Management Board expects a slightly positive result for 2025 and an EBIT margin in the cleary double-digit range from 2026 onwards. While revenue in 2025 will largely come from the operating business of the newly acquired Pharmedix GmbH, the new products ViroCAP® and, in particular, PulmoPlas® will contribute to dynamic growth in the 2026 financial year. The planned revenue is based on existing partnerships and distribution agreements. Werbung Werbung Viromed's low revenue in 2024 is due to the termination of its cooperation with terraplasma medical GmbH, which was announced in July 2024. According to preliminary figures, Viromed has already more than doubled its 2024 revenue in the first half of 2025. In addition, the new developed medical product ViroCAP® is expected to be delivered to customers from September 2025.
Person making the notification:
End of Inside Information Information and Explanation of the Issuer to this announcement: Werbung Werbung About Viromed Medical AG Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region and beyond. Viromed is pursuing the goal of further advancing the use of cold plasma technology in medicine in the coming years and realizing the corresponding growth potential.
E-Mail: kontakt@viromed-medical.de Press contact E-mail: viromed@kirchhoff.de
30-Jun-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Viromed Medical AG |
| Flensburger Straße 18 | |
| 25421 Pinneberg | |
| Germany | |
| E-mail: | kontakt@viromed-medical.de |
| Internet: | https://www.viromed-medical-ag.de/ |
| ISIN: | DE000A3MQR65 |
| WKN: | A3MQR6 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Hamburg, Tradegate Exchange |
| EQS News ID: | 2162604 |
| End of Announcement | EQS News Service |
|
|
2162604 30-Jun-2025 CET/CEST
Ausgewählte Hebelprodukte auf Fonterelli SPAC 2
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Fonterelli SPAC 2
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Nachrichten zu Fonterelli SPAC 2 AG Inhaber-Akt
Analysen zu Fonterelli SPAC 2 AG Inhaber-Akt
Keine Analysen gefunden.